"The ABPI welcomes the sixth paper from the AMR Review Team on vaccines and alternatives to antibiotics. New antibiotics cannot be seen as the only solution to tackle the growing threat of drug-resistant infections and this report recognises the critical roles that vaccines and alternatives can also play." said Dr Virginia Acha, Executive Director - Research, Medical and Innovation today.
"As an industry, our aim is always to support the development of new vaccines to address unmet medical need and benefit health. Vaccines are considered the most effective ways to prevent morbidity and mortality from infectious diseases. However, as this report emphasises vaccines can also play an important role in reducing the development of antibiotic resistance globally as part of a multi-pronged approach to tackle the threat of antimicrobial resistance. The report rightly identifies an immediate priority to make the best use of vaccines that have already been developed alongside the long-term strategy to foster and support new vaccines and other alternatives.
"The Review team again makes the critical link between research investment and sustainable markets in their proposals to support early stage research and "pull incentives", which have delivered success in the past (for example, GAVI). More detail is needed to understand how these different measures would be designed and implemented, and we look forward to engaging in these discussions as they progress.
"The AMR Review team outline the plans to take the collective proposals to the international leadership at the World Health Assembly, the G7, the G20 and the UN General Assembly. Industry is ready to play its part, as set out recently in the Declaration recently launched at Davos, where alongside our members and our association partners, ABPI committed our support."